tbuckley/cabot-search huggingface dataset:
Evidence-based expert consensus on the management of primary central nervous system lymphoma in China
Authors: Tong Chen, Yuanbo Liu, Yang Wang, Qing Chang, Jinsong Wu, Zhiliang Wang, Daoying Geng, Jin-Tai Yu, Yuan Li, Xiao-Qiu Li, Hong Chen, Dongxiao Zhuang, Jianyong Li, Bin Wang, Tao Jiang, Lanting Lyu, Yuqin Song, Xiaoguang Qiu, Wenbin Li, Song Lin, Xinghu Zhang, Dehong Lu, Junqiang Lei, Yaolong Chen, Ying Mao
Journal: Journal of Hematology & Oncology (2022)

Abstract Primary central nervous system lymphoma (PCNSL) is a type of central nervous system restricted non-Hodgkin lymphoma, whose histopathological diagnosis is majorly large B cell lymphoma. To provide specific, evidence-based recommendations for medical professionals and to promote more standardized, effective and safe treatment for patients with PCNSL, a panel of experts from the Chinese Neurosurgical Society of the Chinese Medical Association and the Society of Hematological Malignancies of the Chinese Anti-Cancer Association jointly developed an evidence-based consensus. After comprehensively searching literature and conducting systematic reviews, two rounds of Delphi were conducted to reach consensus on the recommendations as follows: The histopathological specimens of PCNSL patients should be obtained as safely and comprehensively as possible by multimodal tomography-guided biopsy or minimally invasive surgery. Corticosteroids should be withdrawn from, or not be administered to, patients with suspected PCNSL before biopsy if the patient’s status permits. MRI (enhanced and DWI) should be performed for diagnosing and evaluating PCNSL patients where whole-body PET-CT be used at necessary time points. Mini-mental status examination can be used to assess cognitive function in the clinical management. Newly diagnosed PCNSL patients should be treated with combined high-dose methotrexate-based regimen and can be treated with a rituximab-inclusive regimen at induction therapy. Autologous stem cell transplantation can be used as a consolidation therapy. Refractory or relapsed PCNSL patients can be treated with ibrutinib with or without high-dose chemotherapy as re-induction therapy. Stereotactic radiosurgery can be used for PCNSL patients with a limited recurrent lesion who were refractory to chemotherapy and have previously received whole-brain radiotherapy. Patients with suspected primary vitreoretinal lymphoma (PVRL) should be diagnosed by vitreous biopsy. PVRL or PCNSL patients with concurrent VRL can be treated with combined systemic and local therapy.
Relationship Between Carbohydrate Intake (Quantity, Quality, and Time Eaten) and Mortality (Total, Cardiovascular, and Diabetes): Assessment of 2003–2014 National Health and Nutrition Examination Survey Participants
Authors: Wanying Hou, Tianshu Han, Xinyi Sun, Yunyan Chen, Jiaxu Xu, Yu Wang, Xue Yang, Wenbo Jiang, Changhao Sun
Journal: Diabetes Care (2022)

OBJECTIVE In this study we investigated the association of the quantity, quality, and timing of carbohydrate intake with all-cause, cardiovascular disease (CVD), and diabetes mortality. RESEARCH DESIGN AND METHODS This secondary data analysis included use of National Health and Nutrition Examination Survey (2003–2014) and National Death Index data from adults (n = 27,623) for examination of the association of total daily and differences in carbohydrate intake with mortality. Participants were categorized into four carbohydrate intake patterns based on the median values of daily high- and low-quality carbohydrate intake. The differences (Δ) in carbohydrate intake between dinner and breakfast were calculated (Δ = dinner − breakfast). Cox regression models were used. RESULTS The participants who consumed more high-quality carbohydrates throughout the day had lower all-cause mortality risk (hazard ratio [HR] 0.88; 95% CI 0.79–0.99), whereas more daily intake of low-quality carbohydrates was related to greater all-cause mortality risk (HR 1.13; 95% CI: 1.01–1.26). Among participants whose daily high- and low-quality carbohydrate intake were both below the median, the participants who consumed more high-quality carbohydrates at dinner had lower CVD (HR 0.70; 95% CI 0.52–0.93) and all-cause mortality (HR 0.82; 95% CI 0.70–0.97) risk; an isocaloric substitution of 1 serving low-quality carbohydrates intake at dinner with high-quality reduced the CVD and all-cause mortality risks by 25% and 19%. There was greater diabetes mortality among the participants who consumed more low-quality carbohydrates at dinner (HR 1.78; 95% CI 1.02–3.11), although their daily high-quality carbohydrate intake was above the median. CONCLUSIONS Consuming more low-quality carbohydrates at dinner was associated with greater diabetes mortality, whereas consuming more high-quality carbohydrates at dinner was associated with lower all-cause and CVD mortality irrespective of the total daily quantity and quality of carbohydrates.
Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease
Authors: Anna Birukov, Branimir Plavša, Fabian Eichelmann, Olga Kuxhaus, Rosangela Akemi Hoshi, Najda Rudman, Tamara Štambuk, Irena Trbojević-Akmačić, Catarina Schiborn, Jakub Morze, Matea Mihelčić, Ana Cindrić, Yanyan Liu, Olga Demler, Markus Perola, Samia Mora, Matthias B. Schulze, Gordan Lauc, Clemens Wittenbecher
Journal: Diabetes Care (2022)

OBJECTIVE N-glycosylation is a functional posttranslational modification of immunoglobulins (Igs). We hypothesized that specific IgG N-glycans are associated with incident type 2 diabetes and cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)–Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]). Relative abundances of 24 IgG N-glycan peaks (IgG-GPs) were measured by ultraperformance liquid chromatography, and eight glycosylation traits were derived based on structural similarity. End point–associated IgG-GPs were preselected with fractional polynomials, and prospective associations were estimated in confounder-adjusted Cox models. Diabetes risk associations were validated in three independent studies. RESULTS After adjustment for confounders and multiple testing correction, IgG-GP7, IgG-GP8, IgG-GP9, IgG-GP11, and IgG-GP19 were associated with type 2 diabetes risk. A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37–1.64]). Associations of IgG-GPs with CVD risk differed between men and women. In women, IgG-GP9 was inversely associated with CVD risk (hazard ratio [HR] per SD 0.80 [95% CI 0.65–0.98]). In men, a weighted score based on IgG-GP19 and IgG-GP23 was associated with higher CVD risk (HR per SD 1.47 [95% CI 1.20–1.80]). In addition, several derived traits were associated with cardiometabolic disease incidence. CONCLUSIONS Selected IgG N-glycans are associated with cardiometabolic risk beyond classic risk factors, including clinical biomarkers.
Chronic Obstructive Pulmonary Disease Definition: Is It Time to Incorporate the Concept of Failure of Lung Regeneration?
Authors: Marco Confalonieri, Luca Braga, Francesco Salton, Barbara Ruaro, Paola Confalonieri
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

The recent proposal to reclassify chronic obstructive pulmonary disease appropriately identifies environmentally related disease (1).However, in addition to biomass and pollution exposure, the critical role of occupation in the development (2) and worsening (3) of chronic obstructive pulmonary disease should be acknowledged.
Viral loads in clinical samples of men with monkeypox virus infection: a French case series
Authors: Romain Palich, Sonia Burrel, Gentiane Monsel, Agathe Nouchi, Alexandre Bleibtreu, Sophie Seang, Vincent Bérot, Cécile Brin, Ariane Gavaud, Yara Wakim, Nagisa Godefroy, Antoine Fayçal, Yanis Tamzali, Thomas Grunemwald, Michel Ohayon, Eve Todesco, Valentin Leducq, Stéphane Marot, Vincent Calvez, Anne-Geneviève Marcelin, Valérie Pourcher
Journal: The Lancet Infectious Diseases (2022)
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
Authors: François-Clément Bidard, Anne-Claire Hardy-Bessard, Florence Dalenc, Thomas Bachelot, Jean-Yves Pierga, Thibault de la Motte Rouge, Renaud Sabatier, Coraline Dubot, Jean-Sébastien Frenel, Jean Marc Ferrero, Sylvain Ladoire, Christelle Levy, Marie-Ange Mouret-Reynier, Alain Lortholary, Julien Grenier, Camille Chakiba, Laetitia Stefani, Jérôme Edouard Plaza, Florian Clatot, Luis Teixeira, Véronique D'Hondt, Hélène Vegas, Olfa Derbel, Claire Garnier-Tixidre, Jean-Luc Canon, Barbara Pistilli, Fabrice André, Laurent Arnould, Anne Pradines, Ivan Bièche, Céline Callens, Jérôme Lemonnier, Frédérique Berger, Suzette Delaloge, Francois-Clement BIDARD, Barbara PISTILLI, Florence DALENC, Thomas BACHELOT, Thibault DE LA MOTTE ROUGE, Renaud SABATIER, Coraline DUBOT, Jean-Sébastien FRENEL, Jean-Marc FERRERO, Sylvain LADOIRE, Christelle LEVY, Marie-Ange MOURET-REYNIER, Anne-Claire HARDY-BESSARD, Alain LORTHOLARY, Julien GRENIER, Camille CHAKIBA, Laetitia STEFANI, Patrick SOULIE, Jean-Philippe JACQUIN, Jérôme Edouard PLAZA, Florian CLATOT, Luis TEIXEIRA, Véronique D'HONDT, Hélène VEGAS, Olfa DERBEL, Claire GARNIER TIXIDRE, Catherine DELBALDO, Lionel MOREAU, Caroline CHENEAU, Jean-François PAITEL, Chantal BERNARD-MARTY, Dominique SPAETH, Dominique GENET, Isabelle MOULLET, Nathalie BONICHON-LAMICHHANE, Laura DEIANA, Charlotte GREILSAMER, Laurence VENAT-BOUVET, Valérie DELECROIX, Adrien MELIS, Hubert ORFEUVRE, Suzanne NGUYEN, Eric LEGOUFFE, Alain ZANNETTI, Romuald LE SCODAN, Nadine DOHOLLOU, Philippe DALIVOUST, Olivier ARSENE, Nathalie MARQUES, Thierry PETIT, Delphine MOLLON, Jérôme DAUBA, Nathalie BONNIN, François MORVAN, Miriam GARDNER, Adina MARTI, Charles-Briac LEVACHE, Emma LACHAIER, Mihaela ACHILLE, Christophe VALMAR, Ryan BOUAITA, Jacques MEDIONI, Cyril FOA, Chantal BERNARD-MARTY, Francesco DEL PIANO, Michel GOZY, Anne ESCANDE, Nicolas LEDUC, Brigitte LUCAS, Dominique MILLE, Hanifa AMMARGUELLAT, Abeer NAJEM, Fanny TROUBOUL, Philippe BARTHELEMY, Hervé DESCLOS, Didier MAYEUR, Fabrice LORCHEL, François GUINET, Anne-Pascale LAURENTY, Axelle BOUDRANT, Olivier GISSEROT, Corinne ALLEAUME, Aimery DE GRAMONT
Journal: The Lancet Oncology (2022)
Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward
Authors: Kristina Jenei, Zeba Aziz, Christopher Booth, Bernadette Cappello, Francesco Ceppi, Elisabeth G E de Vries, Antonio Fojo, Bishal Gyawali, Andre Ilbawi, Dorothy Lombe, Manju Sengar, Richard Sullivan, Dario Trapani, Benedikt D Huttner, Lorenzo Moja
Journal: The Lancet Global Health (2022)
LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Authors: M. Tsuboi, Y-L. Wu, C. Grohe, T. John, M. Majem Tarruella, J. Wang, T. Kato, J.W. Goldman, S-W. Kim, C-J. Yu, H. Vinh Vu, G. Mukhametshina, C. Akewanlop, F. de Marinis, F.A. Shepherd, D. Urban, M. Stachowiak, A.L. Bolanos, X. Huang, R.S. Herbst
Journal: Annals of Oncology (2022)
LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation
Authors: P.A. Ascierto, M. Mandala, P.F. Ferrucci, M. Guidoboni, P. Rutkowski, V. Ferraresi, A.M. Arance Fernandez, M. Guida, E. Maiello, H.J. Gogas, E. Richtig, M.T. Fierro, C. Lebbe, H. Helgadottir, I. Melero, G. Palmieri, D. Giannarelli, A.M. Grimaldi, R. Dummer, V. Chiarion Sileni
Journal: Annals of Oncology (2022)
LBA43 Intradermal IMO-2125 versus placebo as adjuvant treatment in patients with stage II pT3-4/cN0 melanoma: Interim efficacy and safety results of the randomized phase II INTRIM study
Authors: J.C.L. Notohardjo, S. Veenstra, B.D. Koster, V. Kandiah, S. van der Velde, A.B. Francken, G.A. Gooiker, M.P. van den Tol, M.W. Bekkenk, K.H. in 't Hof, M.E. Straver, B.G. Molenkamp, R.J.C.L.M. Vuylsteke, B.I. Lissenberg-Witte, M. Labots, S.K. Chunduru, A.C.J. van Akkooi, F. Van Den Eertwegh, T.D. de Gruijl
Journal: Annals of Oncology (2022)
LBA1 Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention
Authors: C. Swanton, W. Hill, E. Lim, C. Lee, C.E. Weeden, M. Augustine, K. Chen, F-C. Kuan, F. Marongiu, F. Rodrigues, H. Cha, T. Jacks, M. Luchtenborg, I. Malanchi, J. Downward, C. Carlsten, A. Hackshaw, K.R. Litchfield, J. DeGregori, M. Jamal-Hanjani
Journal: Annals of Oncology (2022)
α&lt;sub&gt;2&lt;/sub&gt;-Macroglobulin Production by Cultured Human Melanoma Cells
Authors: Alton C. Morgan, Jr.
 3
Journal: JNCI Journal of the National Cancer Institute (1984)

α2-Macroglobulin (α2M) was identified in chemically defined spent medium of cultured human melanoma cells. This wide-spectrum protease inhibitor was subsequently shown to be synthesized and was secreted by 10 of 13 cultured melanoma cells but not by neoplastic cells of other histologic origins (0/5 breast, 0/2 colon, 0/2 lung, 0/2 glioblastomas, 0/1 neuroblastoma, 0/4 lymphoid). α2M was also produced by one strain of fetal lung fibroblasts, as was previously shown, but not by two strains of normal fetal uveal melanocytes or two strains of fetal skin fibroblasts. Biochemical characterization of melanoma α2M indicated that it has a similar tetrameric structure but is smaller in size than authentic serum α2M. Preliminary studies indicated that melanoma α2M can bind to protease and has possible functional capability.
Vira Korostovtseva: “We had one homeland…”
Authors: M.P. Chaban, Z.I. Shevtsova, V.V. Gaponov
Journal: GASTROENTEROLOGY (2022)

The article describes the life and professional path of the couple of ascetic doctors Vira Korostovtseva and Petro Teneta. Fate brought them from Ukraine to Central Asia (Kyrgyzstan and Uzbekistan), where they selflessly served in the medical field and were engaged in the social work. The presented material will promote the popularization of the figures of Ukrainian zemstvo doctors.
First International Symposium on Epstein-Barr Virus and Associated Malignant Diseases
Journal: JNCI Journal of the National Cancer Institute (1984)

Journal Article First International Symposium on Epstein-Barr Virus and Associated Malignant Diseases Get access JNCI: Journal of the National Cancer Institute, Volume 72, Issue 4, April 1984, Page 965, https://doi.org/10.1093/jnci/72.4.965-b Published: 01 April 1984
Histo- and morphometric changes in the large intestine mucosa in Crohn’s disease depending on the presence of fibrosis
Authors: U.A. Gaydar, M.V. Stoikevich, D.F. Mylostуva, O.P. Petishko
Journal: GASTROENTEROLOGY (2022)

Background. One of the common complications of Crohn’s disease is the development of fibrotic changes in the wall of the large intestine, and, as a result, the risk of strictures. Morphometric study of the cellular composition of large intestine biopsy samples is one of the extended links of the diagnostic criteria for inflammatory bowel diseases, which make it possible to predict the development of the disease. Changes in the number of fibroblasts, as components of mesenchymal cells, can be considered a protective reaction to the intestinal tissue damage. The purpose of the study was to reveal changes in the histo- and morphometric parameters of the large intestine mucosa depending on the development of intestinal fibrosis in Crohn’s disease. Materials and methods. Colon biopsy samples from patients with Crohn’s disease (n=38) were examined histologically and morphometrically. According to morphological studies, patients were divided into two groups: with fibrotic changes in the intestinal wall (n=10) and without fibrosis (n=28). Results. Histologically, changes in the intestinal mucosa were observed in the form of altered integrity of the epithelium (78.3%), crypt architectonics (34.2%), mucosal edema (28.9%), crypt abscesses (47.3%). Fibrotic changes of the intestinal mucosa were found in 26.3% of patients. The inflammatory infiltrate contained neutrophils, eosinophils, lymphocytes, plasma cells, fibrocytes, and macrophages. At the same time, in the group of patients with Crohn’s disease and fibrosis, the number of representatives of the inflammatory infiltrate was higher than in the group of patients with Crohn’s disease without fibrosis. Patients with fibrotic changes in the intestinal wall were characterized by a higher density of inflammatory infiltrate the composition of which was dominated by macrophages and fibroblasts. Thickening of the intestinal mucosa was also observed in patients with fibrosis. The cause for such changes is the activation of the mechanism of fibrosis development against the background of inflammatory processes. Direct correlations were found between the fibrosis of the colon wall and the depth of crypts (r=0.35; p&lt;0.05), the height of the crypt epithelium (r=0.41; p&lt;0.05), cellular density of the infiltrate (r=0.45; p&lt;0.05), the number of neutrophils (r=0.47; p&lt;0.05), eosinophils (r=0.39; p&lt;0.05), fibroblasts (r=0.57; p&lt;0.05). Conclusions. In colon biopsy samples of patients with Crohn’s disease and intestinal fibrosis, a denser and increased level of inflammatory infiltrate is noted. The active development of the fibrotic process is directly related to the high level of fibroblasts in the infiltrate.
Cytokine profile in patients with atrophic gastritis in comorbidity with thyroid gland pathology
Authors: L.M. Mosiychuk, O.M. Tatarchuk, I.S. Konenko, O.P. Petishko
Journal: GASTROENTEROLOGY (2022)

Background. Optimization of the management of patients with precancerous conditions of the stomach in comorbid pathology is an urgent task of gastroenterology. The purpose of the study: to evaluate the content of pro- and anti-inflammatory cytokines, as well as the level of vascular endothelial growth factor (VEGF) at different degrees of vascularization of the thyroid gland in patients with atrophic gastritis. Materials and methods. A study was conducted in 120 patients with atrophic gastritis and thyroid pathology. All of them underwent a sonological examination of the thyroid gland using an ultrasound scanner Toshiba Xario (Japan), which revealed poor vascularization of the parenchyma in 82 (68.3%) cases, moderate vascularization was diagnosed in 20 (16.7%) patients and marked— in 18 (15.0%). Quantitative content of cytokines (interleukins (IL) 8, 10, 18, tumor necrosis factorα), vascular endothelial growth factor in the blood serum was determined by immunoenzymatic assay using Vector-Best reagents. Results. Among patients with poor vascularization, only atrophic changes of the gastric mucosa were diagnosed in almost half— 39 (47.6%) people, while dysplastic changes of the gastric mucosa were found in a third of patients with marked vascularization. Intestinal metaplasia was detected in half of cases, regardless of the degree of vascularization of the thyroid parenchyma. Cytokine imbalance was found in patients with atrophic gastritis, with the greatest shift in case of marked vascularization of the thyroid parenchyma due to a 4-fold increase in the level of pro-inflammatory cytokines IL-8 (р&lt;0.05) and by 1.7 times of IL-18 (p&lt;0.05), with a simultaneous decrease in the content of the anti-inflammatory cytokine IL-10 by 3.2 times (p&lt;0.05) compared to control indicators. The level of VEGF in the blood serum of patients with atrophic gastritis with moderate and marked vascularization of the thyroid parenchyma was significantly increased by 1.5 (p&lt;0.05) and 1.7 times (p&lt;0.05), respectively, compared to that of people with poor vascularization. Correlations were revealed between the degree of vascularization of the thyroid parenchyma and the level of IL-8 (r=0.491; p=0.031) and VEGF (r=0.444; p=0.019) in patients with atrophic gastritis. Conclusions. Patients with atrophic gastritis had a cytokine imbalance, which deepens as the vascularization of the thyroid gland increases that is possibly related to common pathogenetic mechanisms of the development of comorbid pathology.
Rational choice of hepatoprotectors for drug-induced liver injury
Authors: H.V. Osyodlo, M.P. Boichak, O.O. Fedorova
Journal: GASTROENTEROLOGY (2022)

The article deals with a review of the current literature on the clinical use of hepatoprotectors in drug-induced liver injury. The literature was searched in Scopus, Web of Science, PubMed and other databases. Risk factors, pathogenetic mechanisms of liver damage, international diagnostic criteria and treatment for drug-induced liver injuries are considered. Clinical and pharmacological approaches to the choice of hepatoprotectors for the management of drug-induced liver injury are substantiated. The positive effects of ademetionine, a hepatoprotector, are highlighted— choleretic, cholekinetic, regenerating, antioxidant and antitoxic. In accordance with the principles of evidence-based medicine, it has been found that the indisputable advantage of ademetionine in the comprehensive treatment of drug-induced liver injury is its high clinical effectiveness as a mean of pathogenetic treatment of cholestasis, hepatocellular lesions and their combinations.
Insulin resistance and intestinal microbial metabolites in childhood obesity
Authors: N.Yu. Zavhorodnia, I.A. Klenina, O.M. Tatarchuk, O.I. Hrabovska, O.P. Petishko
Journal: GASTROENTEROLOGY (2022)

The article deals with the study on the content of fecal short-chain fatty acids (SCFA) and their association with insulin resistance in obese children. It was found that intestinal microflora in obese children is characterized by changes in the qualitative composition and increased metabolic activity of the intestinal microflora. A moderate increase of HOMA-IR is accompanied by elevated concentration of anti-inflammatory cytokines, the content of which correlates with that of acetic, propionic acid and a decrease in the metabolic activity of intestinal microflora. The progression of insulin resistance is accompanied by a further increase in the concentration of anti-inflammatory cytokines, the level of HOMA-IR correlates with the level of propionic SCFA. Thus, modulation of SCFA content may be a promising way of therapeutic influence to correct insulin resistance and obesity in children.
LBA39 Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)
Authors: R. Dummer, D. Gyorki, J. Hyngstrom, A. Berger, R. Conry, L. Demidov, L. Ning, T. Lawrence, M. Faries, M. Ross
Journal: Annals of Oncology (2022)
LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
Authors: R.S. Finn, M. Kudo, P. Merle, T. Meyer, S. Qin, M. Ikeda, R. Xu, J. Edeline, B-Y. Ryoo, Z. Ren, A-L. Cheng, P.R. Galle, S. Kaneko, H. Kumada, A. Wang, K. Mody, L. Dubrovsky, A.B. Siegel, J. Llovet
Journal: Annals of Oncology (2022)
1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)
Authors: V.S. Koshkin, T.B. Powles, G. Iyer, Y. Loriot, A. Drakaki, I. Duran Martinez, M. De Santis, M. Retz, R.K. Jain, S. Chan, M. Ichimaru, M.D. Galsky
Journal: Annals of Oncology (2022)
LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)
Authors: M.P. Goetz, M. Toi, J. Huober, J. Sohn, O. Tredan, I.H. Park, M. Campone, S.C. Chen, L.M. Manso Sanchez, S. Paluch-Shimon, G. van Hal, A. Shahir, H. Iwata, S. Johnston
Journal: Annals of Oncology (2022)